Aquestive Therapeutics, Inc. Royalty Expense
Aquestive Therapeutics, Inc. (AQST) reported Royalty Expense of $972.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:RoyaltyExpense · last filed 2026-08-11
- Aquestive Therapeutics, Inc. royalty expense for the quarter ending 2026-06-30 was $972.00K, a 32.22% decline year-over-year.
- Aquestive Therapeutics, Inc. royalty expense for the quarter ending 2026-03-31 was $973.00K, a 32.29% decline year-over-year.
- Aquestive Therapeutics, Inc. royalty expense for the quarter ending 2025-12-31 was $1.43M, a 3.54% increase year-over-year.
- Aquestive Therapeutics, Inc. royalty expense for the quarter ending 2025-09-30 was $1.43M, a 5.45% increase year-over-year.
- Aquestive Therapeutics, Inc. royalty expense for fiscal 2025 was $5.74M, a 5.09% increase from fiscal 2024.
- Aquestive Therapeutics, Inc. royalty expense for fiscal 2024 was $5.46M, a 503.20% increase from fiscal 2023.
- Aquestive Therapeutics, Inc. royalty expense for fiscal 2023 was $905.00K.
- Aquestive Therapeutics, Inc. royalty expense for fiscal 2022 was $0.00.
| Period end | Royalty Expense 3 month | Royalty Expense 6 month | Royalty Expense 9 month | Royalty Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $972.00K 10-Q · filed 2026-08-11 | $1.95M 10-Q · filed 2026-08-11 | $3.38M derived: sum of 3 quarters · filed 2026-08-11 | $4.81M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $973.00K 10-Q · filed 2026-05-13 | $2.41M derived: sum of 2 quarters · filed 2026-05-13 | $3.84M derived: sum of 3 quarters · filed 2026-05-13 | $5.27M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $1.43M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-04 | $2.87M derived: sum of 2 quarters · filed 2026-03-04 | $4.30M derived: sum of 3 quarters · filed 2026-08-11 | $5.74M 10-K · filed 2026-03-04 |
| 2025-09-30 | $1.43M 10-Q · filed 2025-11-05 | $2.87M derived: sum of 2 quarters · filed 2026-08-11 | $4.30M 10-Q · filed 2025-11-05 | $5.69M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $1.43M 10-Q · filed 2026-08-11 | $2.87M 10-Q · filed 2026-08-11 | $4.25M derived: sum of 3 quarters · filed 2026-08-11 | $5.61M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $1.44M 10-Q · filed 2026-05-13 | $2.82M derived: sum of 2 quarters · filed 2026-05-13 | $4.18M derived: sum of 3 quarters · filed 2026-05-13 | $5.54M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $1.38M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-04 | $2.74M derived: sum of 2 quarters · filed 2026-03-04 | $4.10M derived: sum of 3 quarters · filed 2026-03-04 | $5.46M 10-K · filed 2026-03-04 |
| 2024-09-30 | $1.36M 10-Q · filed 2025-11-05 | $2.72M derived: sum of 2 quarters · filed 2025-11-05 | $4.08M 10-Q · filed 2025-11-05 | $4.98M derived: sum of 4 quarters · filed 2025-11-05 |
| 2024-06-30 | $1.36M 10-Q · filed 2025-08-11 | $2.72M 10-Q · filed 2025-08-11 | $3.62M derived: sum of 3 quarters · filed 2025-08-11 | $3.62M derived: sum of 4 quarters · filed 2025-08-11 |
| 2024-03-31 | $1.36M 10-Q · filed 2025-05-12 | $2.26M derived: sum of 2 quarters · filed 2025-05-12 | $2.26M derived: sum of 3 quarters · filed 2025-05-12 | $2.26M derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | $905.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-05 | $905.00K derived: sum of 2 quarters · filed 2025-03-05 | $905.00K derived: sum of 3 quarters · filed 2025-03-05 | $905.00K 10-K · filed 2025-03-05 |
| 2023-09-30 | $0.00 10-Q · filed 2024-11-04 | $0.00 derived: sum of 2 quarters · filed 2024-11-04 | $0.00 10-Q · filed 2024-11-04 | |
| 2023-06-30 | $0.00 10-Q · filed 2024-08-06 | $0.00 10-Q · filed 2024-08-06 | ||
| 2023-03-31 | $0.00 10-Q · filed 2024-05-07 | |||
| 2022-12-31 | $0.00 10-K · filed 2024-03-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |